iSTAR Medical strengthens board with two senior appointments
Dr. Wax is currently the Chief Medical Officer and Executive Vice-President of R&D at PanOptica, Inc., a private biotechnology company specializing in ophthalmic pharmaceuticals. He was Vice President of R&D and Head of Ophthalmology Discovery Research and Preclinical Sciences at Alcon Laboratories from 2003-2008.
Dr. Wax was responsible for the creation and development of the Alcon pharmaceutical portfolio of compounds for the therapeutic areas of glaucoma, retina, allergy, dry eye and anti-infectives.
He is also Clinical Professor of Ophthalmology and Visual Sciences at Rutgers Medical School in Newark, N.J. and has been selected as one of the “Best Doctors in America” 2005-2008 by his peers.
He currently serves as the Chairman of the Board of Directors for Mimetogen, a biotechnology company based in Montreal, Canada. Dr. Wax has co-authored more than 200 publications and is a member of a number of renowned Ophthalmological Associations.
Mr. Nolet de Brauwere was appointed CEO of PhysIOL in 1997 when he took over the company. He previously held different positions at Petrofina S.A. in the US and as an associate at McKinsey.
He is currently an Independent Director at Bone Therapeutics, Cardiatis, Mymicroinvest, Endo Tools Therapeutics, Biotech Coaching and Aliaxis and is currently a Member of the Ashoka Support Network.
He holds a Master’s degree in Civil Mining Engineering from the Université Catholique de Louvain, Belgium and a Master’s degree in Industrial Management from the Katholieke Universiteit Leuven. ■
What to read next
LATEST MOVES FROM Belgium
- VolitionRx appoints David Vanston as CFO
- Jacques Vandermeiren named CEO for Antwerp Port Authority
- Michaël Trabbia appointed CEO of Orange Belgium
- European Commission appoints new director-general
- VolitionRx appoints Louise Day as chief marketing officer
More inside POST
William Hill 17-week revenues rise Earnings